AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6340970
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin daily for 3 months
Trial: 29656569
Drug: Small‐quantity lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small‐quantity lipid‐based nutrient supplements (SQ‐LNS)
Trial: 18160927
Drug: Point injection
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point injection
Trial: 16336289
Drug: Tiotropium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium therapy alone (Control)
Trial: 31194943
Drug: Early clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early clinical assessment of dysphagia before oral intake; therapeutic interventions implemented immediately for diagnosed dysphagia
Trial: 28244408
Drug: GemX (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GemX (gemcitabine chemotherapy at 100 mg/m2 with concurrent radiation therapy at a total dose of 52.5 Gy in 20 fractions)
Trial: 28244408
Drug: neoGemX (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoGemX (gemcitabine chemotherapy at 100 mg/m2 with concurrent radiation therapy at a total dose of 52.5 Gy in 20 fractions following NAC)
Trial: 26718518
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with clopidogrel (triple-C)
Trial: 26718518
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with prasugrel (triple-P)
Trial: 26718518
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with clopidogrel (dual-C)
Trial: 26718518
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with prasugrel (dual-P)
Trial: 26718518
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (both triple-C and triple-P)
Trial: 22892368
Drug: Multi-sugar (MS)
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-sugar (MS) test (1 g sucrose, lactulose, sucralose, erythritol, 0.5 g rhamnose in water) after indomethacin
Trial: 22892368
Drug: Dual sugar
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual sugar (DS) test (5 g lactulose, 0.5 g rhamnose) after indomethacin
Trial: 15471656
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg/day)
Trial: 11915694
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control Group 3, 30 patients)
Trial: 7976142
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 0.5% lidocaine with 2 mg of atracurium
Trial: 7976142
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 0.5% lidocaine
Trial: 27783162
Drug: Subcutaneous closed-suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous closed-suction drainage arm
Trial: 27783162
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (no subcutaneous drainage)
Trial: 21519837
Drug: CEF adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF adjuvant chemotherapy
Trial: 21519837
Drug: CMF adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF adjuvant chemotherapy
Trial: 18370574
Drug: Aripiprazole (5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5-30 mg/day)
Trial: 16565827
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (7 or 14 mg)
Trial: 11090796
Drug: 60-minute determination
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute determination of ST-segment resolution after thrombolytic therapy
Trial: 11090796
Drug: 90-minute determination
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-minute determination of ST-segment resolution after thrombolytic therapy
Trial: 1526219
Drug: 3,4-diaminopyridine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-diaminopyridine + anti-cholinesterase medication
Trial: 2989052
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g bran daily
Trial: 29126173
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) at all time points (Arm A)
Trial: 29126173
Drug: Bivalent oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent oral poliovirus vaccine (bOPV) at all time points (Arm B)
Trial: 29126173
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) at final time point (Arm D)
Trial: 26983976
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (once-per-day)
Trial: 26983976
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical corticosteroids
Trial: 24671338
Drug: Dextroamphetamine (sensitising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (sensitising dosage pattern)
Trial: 22464810
Drug: Golden Delicious
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golden Delicious apple juice (300 mL)
Trial: 22464810
Drug: Catarina apple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catarina apple juice (300 mL)
Trial: 17823908
Drug: Docetaxel/gemcitabine (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/gemcitabine (docetaxel 30 mg/m(2) + gemcitabine 800 mg/m(2))
Trial: 17823908
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (36 mg/m(2))
Trial: 15339495
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid plus kidney-warming and astringent therapy (treatment group)
Trial: 15339495
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid treatment (control group)
Trial: 11691528
Drug: Dual-chamber pacemaker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-chamber pacemaker implant (paced patients)
Trial: 11691528
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (controls)
Trial: 2690768
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/day)
Trial: 2801831
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (100 mg/day)
Trial: 49745
Drug: Intermittent short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent short duration intravenous infusions
Trial: 31376356
Drug: Maltodextrin-based feed
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 20 g/kg
Trial: 31376356
Drug: Maltodextrin-based feed
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 10 g/kg
Trial: 31376356
Drug: Maltodextrin-based feed
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 0 g/kg
Trial: 26908424
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsules containing MK-7
Trial: 26908424
Drug: Soft gel
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gel capsules
Trial: 23185760
Drug: Ginkgo Biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Biloba Tablet (GBT), 1 tablet each time, 3 times a day for 12 months
Trial: 23185760
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic treatment only)
Trial: 19829141
Drug: Local intracoronary
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local intracoronary infusion of abciximab through the ClearWayRX System
Trial: 19829141
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of abciximab via the guiding catheter
Trial: 19829141
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive intravenous infusion of abciximab during the 12‐h period following the procedure
Trial: 17608573
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment (160 mJ/pulse at 10 Hz)
Trial: 17608573
Drug: Ultrasonic scaler
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaler treatment
Trial: 11261739
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die administered at 10.00 PM
Trial: 11261739
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die administered at 8.00 AM
Trial: 11261739
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die administered at 4.00 PM
Trial: 11261739
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die administered at night (10.00 PM)
Trial: 1961957
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction (2.5 mg/kg)
Trial: 1961957
Drug: Thiopental induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental induction (4-5 mg/kg)
Trial: 20310020
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g mesalamine suppository once daily
Trial: 20310020
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g mesalamine suppository thrice daily
Trial: 12150347
Drug: 10% triacylglycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% triacylglycerol emulsion (500 ml, 450 Kcal)
Trial: 12150347
Drug: 20% triacylglycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% triacylglycerol emulsion (500 ml, 900 Kcal)
Trial: 7597305
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with IFN alpha and high-dose IL-2
Trial: 7597305
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with dacarbacine (DTIC) followed by IFN-alpha
Trial: 7597305
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of DTIC or cisplatinum (CDDP) followed by IFN-alpha/IL-2
Trial: 6975997
Drug: Phenprocoumon (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenprocoumon (oral anticoagulant therapy)
Trial: 6975997
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral anticoagulant therapy)
Trial: 31856909
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus Denosumab (120 mg every 2 weeks, following nivolumab)
Trial: 15082280
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg/kg intravenously after induction, maintained with 0.5 mg/kg per hour)
Trial: 8957982
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 0.3 mol litre‐1 (antacid)
Trial: 8957982
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate dehydrate (100 mg ml‐1) with citric acid monohydrate (66 mg ml‐1) (buffer)
Trial: 8957982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gastric solution)
Trial: 7687142
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight hydroxyethyl starch solution (LMW‐HES) (6% HES; mean molecular weight 200,000 Da, molar substitution 0.5)
Trial: 3698726
Drug: Single-dose mezlocillin
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose mezlocillin (5 grams preoperative)
Trial: 3698726
Drug: Multiple-dose mezlocillin
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose mezlocillin (3 doses of 2 grams perioperative)
Trial: 30414284
Drug: OIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIT with pasteurized egg white (PEW) - daily 3.3 g proteins (AG)
Trial: 22882698
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m²) plus cisplatin (75 mg/m²)
Trial: 22882698
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m² on days 1 and 8) plus cisplatin (75 mg/m²)
Trial: 15260907
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP)
Trial: 15260907
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP) in females
Trial: 15260907
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP) in males
Trial: 11416734
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruptions (STI) in 12 patients
Trial: 8361472
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg per day added to immuno-chemotherapy (Tegaful, Mitomycin, Krestin, OK-432)
Trial: 8361472
Drug: Tamoxifen in
RxNorm normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen in cases with estrogen receptor
Trial: 8361472
Drug: Tamoxifen in
RxNorm normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen in cases without estrogen receptor
Trial: 21760633
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference
Trial: 8896540
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (Oka/SB Bio)
Trial: 1803786
Drug: Lanoxin 0.125
RxNorm normalized name: Lanoxin 0.125mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxin 0.125 mg
Trial: 1803786
Drug: Lanoxicaps 0.1
RxNorm normalized name: Lanoxicaps 0.1mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxicaps 0.1 mg
Trial: 1803786
Drug: Lanoxin 0.25
RxNorm normalized name: Lanoxin 0.25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxin 0.25 mg
Trial: 1803786
Drug: Lanoxicaps 0.2
RxNorm normalized name: Lanoxicaps 0.2mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxicaps 0.2 mg
Trial: 26037245
Drug: Doxazosin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (titrated to 16 mg/day)
Trial: 9612619
Drug: Adjuvant 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant 5-fluorouracil based chemotherapy
Trial: 7751115
Drug: Titanium-reinforced membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium-reinforced membrane and osseointegrated implants
Trial: 2661788
Drug: Metoclopramide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.1 mg/kg four times a day, 1/2 hour before feeding for 1 week
Trial: 29931294
Drug: Traditional orthodontic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional orthodontic treatment (Control)
Trial: 25713025
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin use (moderate versus nonregular use)
Trial: 27029746
Drug: Ibuprofen use
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen use
Trial: 16507028
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment programme for depression
Trial: 10945511
Drug: Estradiol matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol matrix transdermal system (0.1 mg/d)
Trial: 10945511
Drug: Estradiol matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol matrix transdermal system (0.05 mg/d)
Trial: 10945511
Drug: Estradiol matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol matrix transdermal system (0.0375 mg/d)
Trial: 10945511
Drug: Estradiol matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol matrix transdermal system (0.025 mg/d)
Trial: 10945511
Drug: Estradiol matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol matrix transdermal system (all doses)
Trial: 1308130
Drug: Intensive control
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive control with a step-up regimen including insulin alone or insulin/glipizide combinations
Trial: 1308130
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group with insulin
Trial: 6363659
Drug: Antenatal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antenatal dexamethasone administration
Trial: 3890036
Drug: Mepivacaine carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine carbonate (1% solution)
Trial: 29266879
Drug: Celecoxib (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100-200 mg twice daily)
Trial: 29266879
Drug: Ibuprofen (600-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600-800 mg 3 times daily)
Trial: 31448533
Drug: Lactulose (Gp-L)
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose (Gp-L)
Trial: 31448533
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Gp-NL)
Trial: 29231522
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of moxibustion along the governor vessel and the conception vessel with salazosulfapyridine (SASP)
Trial: 29231522
Drug: Routine moxibustion
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine moxibustion therapy
Trial: 20179727
Drug: Phytosphingosine (PS)
DrugBank: Phytosphingosine (DB14119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosphingosine (PS) 500 mg twice daily
Trial: 12487780
Drug: F(ab')(2) FRaMon
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F(ab')(2) FRaMon 0.2 mg/kg
Trial: 12487780
Drug: F(ab')(2) FRaMon
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F(ab')(2) FRaMon 0.25 mg/kg
Trial: 7865980
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 5.7, 11.4, and 17.1 pmol kg‐1 min‐1 CDD/ANP‐99‐126
Trial: 7865980
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of CDD/ANP‐99‐126